OCD1 Stock Overview
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ChromaDex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.68 |
| 52 Week High | US$4.06 |
| 52 Week Low | US$1.17 |
| Beta | 1.99 |
| 1 Month Change | 39.39% |
| 3 Month Change | 192.06% |
| 1 Year Change | 189.76% |
| 3 Year Change | -41.59% |
| 5 Year Change | -4.19% |
| Change since IPO | 59.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCD1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.2% | -9.3% | -1.5% |
| 1Y | 189.8% | -11.2% | 0.9% |
Return vs Industry: OCD1 exceeded the German Life Sciences industry which returned -9.5% over the past year.
Return vs Market: OCD1 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| OCD1 volatility | |
|---|---|
| OCD1 Average Weekly Movement | 13.6% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OCD1's share price has been volatile over the past 3 months.
Volatility Over Time: OCD1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 106 | Rob Fried | www.chromadex.com |
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex Corporation Fundamentals Summary
| OCD1 fundamental statistics | |
|---|---|
| Market cap | €281.51m |
| Earnings (TTM) | -€4.64m |
| Revenue (TTM) | €78.51m |
3.4x
P/S Ratio-57.9x
P/E RatioIs OCD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCD1 income statement (TTM) | |
|---|---|
| Revenue | US$83.57m |
| Cost of Revenue | US$32.79m |
| Gross Profit | US$50.78m |
| Other Expenses | US$55.72m |
| Earnings | -US$4.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.065 |
| Gross Margin | 60.76% |
| Net Profit Margin | -5.91% |
| Debt/Equity Ratio | 0% |
How did OCD1 perform over the long term?
See historical performance and comparison